
The author argues that combining SORA and FGF21 can enhance the sensitivity of hepatocellular carcinoma cells to treatment under hypoxic conditions, potentially improving outcomes for patients.


coremsg

Hepatocellular carcinoma (HCC) is a common human disease and one of the main causes of cancer-related death. The angiogenesis inhibitor Sorafenib (SORA) is commonly used in the treatment of advanced HCC as a first-line drug.

Study suggests the possibility of combination therapy of SORA and FGF21 in hepatocellular carcinoma

Combination-Therapy-of-SORA-and-FGF21-in-Hepatocellular-Carcinoma


Combination Therapy of SORA and FGF21 in Hepatocellular Carcinoma
